Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Oberst

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Molecular Cancer Research : MCR|April 23, 2021
Distinct Biomarker Profiles and TCR Sequence Diversity Characterize the Response to PD-L1 Blockade in a Mouse Melanoma ModelRajaa El Meskini, Devon Atkinson, Alan Kulaga, et al.
Nature Medicine|April 28, 2026
Clinical trials for continuously monitored and updated AI systemsWouter A C van Amsterdam, Michael Oberst, Jean Feng, et al.
Journal for Immunotherapy of Cancer|August 24, 2019
Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignanciesAung Naing, Jeffrey Infante, Sanjay Goel, et al.
Mabs|January 5, 2021
Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancerDarren J Schofield, Jennifer Percival-Alwyn, Mateusz Rytelewski, et al.
Medrxiv : the Preprint Server for Health Sciences|January 7, 2025
A Novel Playbook for Pragmatic Trial Operations to Monitor and Evaluate Ambient Artificial Intelligence in Clinical PracticeMajid Afshar, Felice Resnik, Mary Ryan Baumann, et al.
Molecular Therapy. Oncology|April 10, 2024
Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12Cheyne Kurokawa, Sonia Agrawal, Abhisek Mitra, et al.
NEJM AI|September 17, 2025
A Novel Playbook for Pragmatic Trial Operations to Monitor and Evaluate Ambient Artificial Intelligence in Clinical PracticeMajid Afshar, Felice Resnik, Mary Ryan Baumann, et al.
Oncoimmunology|April 14, 2017
MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potentialNatalie J Tigue, Lisa Bamber, John Andrews, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Molecular Cancer Research : MCR|April 23, 2021
Distinct Biomarker Profiles and TCR Sequence Diversity Characterize the Response to PD-L1 Blockade in a Mouse Melanoma ModelRajaa El Meskini, Devon Atkinson, Alan Kulaga, et al.
Nature Medicine|April 28, 2026
Clinical trials for continuously monitored and updated AI systemsWouter A C van Amsterdam, Michael Oberst, Jean Feng, et al.
Journal for Immunotherapy of Cancer|August 24, 2019
Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignanciesAung Naing, Jeffrey Infante, Sanjay Goel, et al.
Mabs|January 5, 2021
Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancerDarren J Schofield, Jennifer Percival-Alwyn, Mateusz Rytelewski, et al.
Medrxiv : the Preprint Server for Health Sciences|January 7, 2025
A Novel Playbook for Pragmatic Trial Operations to Monitor and Evaluate Ambient Artificial Intelligence in Clinical PracticeMajid Afshar, Felice Resnik, Mary Ryan Baumann, et al.
Molecular Therapy. Oncology|April 10, 2024
Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12Cheyne Kurokawa, Sonia Agrawal, Abhisek Mitra, et al.
NEJM AI|September 17, 2025
A Novel Playbook for Pragmatic Trial Operations to Monitor and Evaluate Ambient Artificial Intelligence in Clinical PracticeMajid Afshar, Felice Resnik, Mary Ryan Baumann, et al.
Oncoimmunology|April 14, 2017
MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potentialNatalie J Tigue, Lisa Bamber, John Andrews, et al.
Pageof 4